Ovarian Cancer Screening and CA-125: Why There Is Still No Routine Test, and Who Is Monitored

Scroll through social media this month and you will find the same post shared thousands of times: a woman, mid-forties, holding a lab printout and urging every friend to “demand a CA-125 at your next physical.” Alongside it run headlines about a university ultrasound program that reported better survival in the women it screened. As of September 2026, ovarian cancer screening is trending for the first time in years, and the questions landing in clinic inboxes are urgent: Why is there still no routine test? Should I ask for one anyway?

The honest answer is more interesting than either the viral post or the headline. Researchers have spent three decades and more than 280,000 volunteers trying to make ovarian cancer screening work. The results were clear, repeatable, and disappointing. Yet a specific group of women is monitored closely, and knowing whether you belong to it matters far more than any single blood test.

This piece walks through what CA-125 can and cannot do, what the trials actually found, and who should be having a very different conversation with their clinician.

What changed recently in ovarian cancer screening

Nothing in the formal guidance has shifted, which is itself the story. The U.S. Preventive Services Task Force reaffirmed its grade D recommendation against screening asymptomatic, average-risk women in February 2018, and that position still stands. A grade D means the Task Force concluded, with moderate certainty, that the harms outweigh any benefit. The CDC’s current ovarian cancer pages carry the same message: there is no simple, reliable way to screen for the disease in women who have no symptoms and no elevated risk.

What did change is the weight of evidence behind that stance. In May 2021, the Lancet published the final analysis of UKCTOCS, the United Kingdom Collaborative Trial of Ovarian Cancer Screening, after a median follow-up of 16.3 years. It is the largest randomized screening trial ever run for any cancer, with 202,638 postmenopausal women. The multimodal arm, which tracked CA-125 over time and added ultrasound when the pattern looked suspicious, did catch more cancers at stage I and fewer at stage IV. It did not reduce deaths. Neither did annual ultrasound alone.

Why the topic resurfaced in 2026 has less to do with new data than with two things colliding: a single-arm screening program in the United States reporting encouraging survival numbers, and the growing visibility of blood tests marketed as able to detect many cancers at once. Both are easy to misread. A single-arm study has no comparison group, so it cannot tell whether earlier detection changed anyone’s outcome or simply moved the diagnosis date forward. And the multi-cancer tests remain investigational for ovarian cancer, with no randomized evidence that they save lives. The rest of this article explains why those distinctions are not academic hairsplitting.

Is there a routine ovarian cancer screening test?

Not for most women, and not for lack of trying. Screening, in the medical sense, means testing people who feel perfectly well in order to find disease before symptoms appear. It is a different act from diagnostic testing, which investigates a symptom or a finding that is already there. Mammography, colonoscopy and the Pap or HPV test all earned their place by showing, in randomized trials, that finding disease early actually prevented deaths. Ovarian cancer has no equivalent.

The two candidate tools have been studied exhaustively. One is CA-125, a protein measured in blood. The other is transvaginal ultrasound, a scan performed with a slim probe placed in the vagina to image the ovaries and fallopian tubes in detail. Used alone or together, annually or with sophisticated algorithms tracking change over time, they have failed to lower ovarian cancer mortality in the two trials large enough to answer the question.

Part of the problem is arithmetic. Ovarian cancer affects roughly 1 in 80 to 1 in 90 women over a lifetime, far fewer than breast or colorectal cancer. When a disease is rare, even a very accurate test generates many more false alarms than true finds, and for the ovaries a false alarm often means surgery. Part of the problem is biology, which later sections unpack: the most lethal subtype tends to spread while the tumor is still too small for any current test to see.

Every major body that has reviewed the evidence reached the same conclusion. The NHS does not offer a national ovarian cancer screening program. The CDC states plainly that no screening test has proven effective. For women at average risk, the recommended approach is awareness of persistent new symptoms and prompt evaluation, not a scheduled test.

What is the CA-125 blood test and what does it measure?

CA-125 stands for cancer antigen 125. It is a protein found on the surface of many ovarian cancer cells and also on the lining of the abdomen, chest and pelvis. When that lining is irritated, inflamed or stretched, cells shed more of the protein into the bloodstream, and a lab can measure it.

The test itself is ordinary: a single tube of blood, the same as a cholesterol check. Laboratories report the result in units per milliliter against a reference range, and most use a conventional upper limit as the dividing line between “normal” and “elevated.” That line is a statistical convenience, not a verdict. Many women with ovarian cancer sit below it, and many women with no cancer at all sit above it.

Where CA-125 genuinely earns its keep is after a diagnosis. In women with advanced epithelial ovarian cancer, the most common type, roughly 80 percent have a raised CA-125 at the outset. Oncologists then use the trend as a barometer: a falling level during chemotherapy suggests the treatment is working, a stable level suggests control, and a rising level after treatment can signal recurrence months before scans show it. MedlinePlus describes this monitoring role as the test’s primary purpose.

It is also used, cautiously, as one input when a woman already has a pelvic mass found on ultrasound. Combined with imaging features, age and menopausal status, it helps clinicians judge how likely the mass is to be cancer and whether a gynecologic oncologist should be involved before any surgery. That triage role is well supported. Using the same number to hunt for hidden cancer in healthy women is where the evidence collapses.

Why CA-125 misses early disease and flags benign conditions

Think of CA-125 as a smoke detector wired to a very sensitive sensor placed in the wrong room. It reacts to many fires, and it often fails to react to the one you care about until the flames are visible from the street.

The sensitivity problem comes first. Sensitivity is a test’s ability to flag the disease when the disease is present. For stage I ovarian cancer, the stage at which treatment has the best chance of succeeding, only about half of women have a CA-125 above the conventional threshold. A tumor confined to one ovary simply may not shed enough protein to register. By the time the level climbs reliably, disease has often spread across the peritoneum, the membrane lining the abdominal cavity.

The specificity problem follows. Specificity is a test’s ability to stay quiet when disease is absent. CA-125 rises with endometriosis, uterine fibroids, pelvic inflammatory disease, menstruation, pregnancy, liver cirrhosis, heart failure, recent abdominal surgery, and cancers of the pancreas, breast, lung and colon. In premenopausal women the list of benign triggers is so long that an elevated result is far more likely to reflect a period or a fibroid than a malignancy. That is why trials have focused on postmenopausal women, where the background noise is lower.

Researchers tried to outsmart the limitations. The UKCTOCS multimodal arm used the Risk of Ovarian Cancer Algorithm, which watches each woman’s personal CA-125 trajectory rather than a fixed cutoff, on the theory that a steady climb from a low baseline is more telling than a single high number. The algorithm did improve detection of early-stage disease. It still did not save lives, which brings us to the evidence itself.

What the evidence actually says: grading two decades of trials

Medical evidence comes in tiers, and the tier matters as much as the finding. Randomized controlled trials sit at the top because they assign participants to screening or no screening by chance, so the two groups differ only in the intervention. Observational cohorts and single-arm programs sit lower: they can describe what happened to the people screened, but not what would have happened without screening. Expert opinion sits lowest and fills the gaps where no trial exists.

For ovarian cancer screening in average-risk women, the evidence is unusually strong and unusually consistent, and it is strong in the direction of no benefit.

The PLCO trial, run by the National Cancer Institute, randomized 78,216 American women aged 55 to 74 between 1993 and 2001. The screened group received annual CA-125 for six years and transvaginal ultrasound for four. After a median of about 12 years, ovarian cancer deaths were 118 in the screened group and 100 in the usual-care group. There was no stage shift and no mortality benefit. Among women with false-positive results, more than a thousand underwent surgery, and roughly 15 percent of those suffered at least one serious complication.

UKCTOCS, with 202,638 British women aged 50 to 74, tested two strategies against no screening. The multimodal arm shifted the stage distribution earlier. The ultrasound arm did not. Neither reduced deaths over 16 years. The authors concluded that general population screening with these tools cannot be recommended.

Grade that evidence honestly: two high-quality randomized trials, enormous sample sizes, long follow-up, concordant results. By contrast, the recent single-arm ultrasound program that generated headlines is observational, lacks a control group, and is vulnerable to lead-time and length-time bias, concepts explained in the next sections. Its findings are hypothesis-generating, not practice-changing.

PLCO vs UKCTOCS at a glance

Numbers tell this story better than adjectives. The table below summarizes the two randomized trials that define what we know about ovarian cancer screening in women without a known inherited risk. Figures are rounded from the published reports.

Feature	PLCO (United States)	UKCTOCS (United Kingdom)
Women randomized	78,216	202,638
Age at entry	55–74	50–74
Enrollment years	1993–2001	2001–2005
Screening tested	Annual CA-125 (6 years) plus annual transvaginal ultrasound (4 years)	Arm 1: CA-125 tracked by algorithm, ultrasound if abnormal. Arm 2: annual ultrasound alone
Median follow-up	About 12 years	16.3 years
Earlier-stage detection?	No	Yes in the CA-125 algorithm arm (about 47% more stage I, 24% fewer stage IV); no in the ultrasound arm
Fewer ovarian cancer deaths?	No (118 vs 100 deaths, screened vs control)	No statistically significant reduction in either arm
Surgery for false positives	About 1,080 operations; roughly 15% had a serious complication	Substantially higher in the ultrasound arm; fewer in the algorithm arm

Two patterns deserve a second look. First, the trials used different ages, different intervals and different analytic methods, yet landed in the same place. That convergence is what makes the conclusion robust rather than a quirk of one study design. Second, UKCTOCS shows that catching more early-stage cancers is not the same as saving lives. That gap between detection and survival is the single most misunderstood fact in this entire debate, and it deserves its own explanation.

Why earlier detection did not translate into fewer deaths

If the CA-125 algorithm in UKCTOCS found nearly half again as many stage I cancers, how could it fail to prevent a single death? The answer lies in three ideas that every screening scientist carries around, and that rarely make it into a viral post.

Lead-time bias is the first. Imagine two women with identical tumors. One is diagnosed by screening at year three; the other waits for symptoms at year five. Both die at year eight. The screened woman appears to have “survived five years” versus three, yet she gained nothing except a longer time knowing. Survival statistics measured from diagnosis will always flatter screening, even when it changes nothing. Only death rates measured from randomization avoid the trap, which is why the trials report deaths rather than five-year survival.

Length-time bias is the second. Slow-growing tumors linger in a detectable, pre-symptomatic window for years, so periodic screening catches them disproportionately. Fast-growing tumors flash through that window between annual checks and present with symptoms. Screening therefore preferentially finds the cancers that were going to do well anyway.

Biology is the third, and for ovarian cancer it is decisive. High-grade serous carcinoma, the subtype responsible for most deaths, now appears to begin in the fimbrial end of the fallopian tube, not the ovary. Cells can shed into the abdominal cavity while the primary lesion is only millimeters across, far below the resolution of ultrasound and long before CA-125 rises. The extra stage I cancers found in UKCTOCS were likely weighted toward the less aggressive subtypes. The tumors that kill had, in effect, already left the building.

That is not a counsel of despair. It is a precise diagnosis of why the current tools fall short, and it points directly at what a future test would need to detect.

What are the harms of screening women at average risk?

A test that cannot help can still hurt, and for the ovaries the hurt is concrete. Unlike a suspicious mammogram, which can be resolved with a needle biopsy, a suspicious ovarian finding usually cannot be safely sampled through the skin, because puncturing a cancerous cyst risks spreading cells. The only way to know is to remove the ovary and often the tube, and that means an operation under general anesthesia.

PLCO quantified the cost in human terms. Nearly 3,300 women received a false-positive result, meaning the test flagged cancer that was not there. About a third of them went to surgery. Of those operated on, roughly one in seven had a serious complication: infection, bowel or bladder injury, bleeding requiring transfusion, or a cardiovascular event. Each of those women had been healthy the morning she walked into the screening clinic.

There is a quieter harm too. Removing both ovaries before natural menopause drops estrogen abruptly, with downstream effects on bone density and cardiovascular risk that persist for decades. A woman in her fifties who loses healthy ovaries to a false alarm has traded a hypothetical cancer for real, measurable consequences.

Then comes the psychological toll: the weeks between an abnormal result and a benign pathology report, the follow-up scans, the conversations with family. Surveys from both trials documented transient but genuine anxiety, and for some women the fear outlasted the all-clear.

Weigh these against the benefit side of the ledger, which in average-risk women is, on the best available evidence, zero. That is the calculation behind a grade D recommendation. It is not a judgment that ovarian cancer does not matter. It is a judgment that this particular test, in this particular population, does more harm than good.

What do ovarian cancer screening guidelines say?

Guidelines on this topic are remarkably aligned across countries, which is rare in preventive medicine. The language differs; the substance does not.

In the United States, the Preventive Services Task Force recommends against screening for ovarian cancer in asymptomatic women who are not known to carry a high-risk hereditary syndrome. The recommendation explicitly covers CA-125 and transvaginal ultrasound. The CDC echoes this on its public pages and adds a practical point: a Pap test, which checks the cervix, does not screen for ovarian cancer, a misunderstanding that surfaces constantly in clinic.

In the United Kingdom, the NHS has no national screening program for ovarian cancer and states that current tests are not reliable enough to use across the population. The National Screening Committee reviewed the UKCTOCS results and maintained that position.

Professional societies in gynecologic oncology take the same line for average-risk women, while carving out a separate pathway for those with inherited risk. That pathway is not technically “screening” in the population sense; it is individualized surveillance offered to a small, well-defined group whose baseline risk is many times higher.

Why does the consistency matter? Because the viral framing of “doctors are hiding a simple test” does not survive contact with the documents. Independent panels in different health systems, with different incentives and different funding models, examined the same trials and reached the same answer. The absence of a routine test is not an oversight or a cost-saving dodge. It is the evidence-based position, and it will change only when a new test demonstrates, in a randomized trial, that it lowers deaths without unacceptable harm.

For the reader, the practical takeaway is simple: if you have no symptoms and no known inherited risk, your clinician is following the guidance by not ordering a CA-125.

Who is monitored for ovarian cancer, and how?

The group that does receive structured attention is defined by genetics and family history rather than age. Women who carry a pathogenic variant in BRCA1 or BRCA2 face a lifetime ovarian cancer risk in the range of roughly 40 percent and 15 to 20 percent respectively, compared with a little over 1 percent in the general population. Lynch syndrome, an inherited condition caused by faulty DNA mismatch-repair genes, raises risk to around 10 percent or more. Variants in genes such as BRIP1, RAD51C, RAD51D and PALB2 carry smaller but still meaningful increases. A strong family history, especially of ovarian cancer in a first-degree relative or multiple cases of breast and ovarian cancer, prompts referral for genetic counseling and testing.

For these women, the recommended risk-reducing strategy is not a test at all. It is surgery: removal of both fallopian tubes and ovaries, known as risk-reducing salpingo-oophorectomy, once childbearing is complete. Guidelines suggest a window generally between the mid-thirties and mid-forties depending on the gene involved, timed in consultation with a gynecologic oncologist. Observational data show this reduces ovarian cancer risk by roughly 80 percent or more. Because surgery triggers menopause, the decision involves careful discussion of hormone considerations with the treating clinician.

Surveillance with CA-125 and transvaginal ultrasound, typically every six months, is offered to high-risk women who have not yet had surgery or who choose to defer it. Honesty about its evidence grade matters: this is expert opinion supported by small cohort studies, not randomized trial proof. The United Kingdom Familial Ovarian Cancer Screening Study found that intensive monitoring in high-risk women detected more early-stage disease, but it could not show a survival benefit. Monitoring is a bridge, not a safety net.

If any of this describes your family, the most useful step is a genetics referral. Everything else follows from the result.

What tests are done to check for ovarian cancer when something is wrong?

Here the vocabulary shifts from screening to diagnosis, and the tools that were unhelpful in healthy women become genuinely valuable. When a woman reports persistent new pelvic or abdominal symptoms, or a clinician feels a mass on examination, an evaluation typically unfolds in layers.

It usually begins with a pelvic examination and a transvaginal ultrasound, which can distinguish a fluid-filled simple cyst, almost always benign, from a complex mass with solid components, septations or abnormal blood flow. Ultrasound findings are scored against standardized criteria that estimate the likelihood of malignancy.

A CA-125 blood test is often drawn alongside the scan. In a postmenopausal woman with a suspicious mass, a markedly elevated level raises concern substantially; in a premenopausal woman the same number is interpreted with far more caution for the reasons described earlier. Some laboratories also measure HE4, a second protein, and combine the two in a calculation called ROMA, the Risk of Ovarian Malignancy Algorithm, to refine the estimate.

If concern persists, a CT scan of the abdomen and pelvis maps the extent of any disease and checks for fluid, enlarged lymph nodes or deposits on the peritoneum. MRI may be used to characterize an indeterminate mass. Occasionally a sample of abdominal fluid is drawn and examined for cancer cells.

The definitive answer comes from surgery. A gynecologic oncologist removes the mass, often with the ovary and tube, and a pathologist examines the tissue. When cancer is confirmed, the same operation usually serves to stage the disease and remove as much tumor as possible. Mayo Clinic and the NHS both describe this sequence, and both stress a point that bears repeating: outcomes are better when a specialist in gynecologic cancers performs the first operation, so early referral matters.

What is on the horizon for ovarian cancer screening research?

The failure of CA-125 and ultrasound did not end the search; it redirected it toward the fallopian tube and toward signals that appear before a tumor is large enough to image.

Multi-cancer early detection blood tests are the most visible candidates. They look for fragments of tumor DNA circulating in the blood, often identifying cancer by the chemical tags, called methylation patterns, that cells use to switch genes on and off. Early studies show these tests can detect some advanced ovarian cancers, but sensitivity for stage I disease is low, and no randomized trial has yet shown that using them reduces deaths from ovarian cancer or any other cancer. Several large trials are underway. Until they report, these products are investigational for this purpose and are not a substitute for established care.

Other approaches sample closer to the source. Researchers have tested whether cells or DNA collected during a routine Pap smear or with a uterine brush can carry mutations from a tube or ovary cancer upstream. Proof-of-concept studies are intriguing; population-scale accuracy is unknown.

Prevention research may deliver sooner. Because high-grade serous cancer appears to start in the fallopian tube, surgeons increasingly offer opportunistic salpingectomy, removal of the tubes during another pelvic operation such as hysterectomy or tubal sterilization, while leaving the hormone-producing ovaries in place. Observational data suggest a meaningful reduction in later ovarian cancer, and the procedure adds little to the original surgery. It is a decision for a woman and her surgeon, not a screening test, but it is one of the few interventions available to average-risk women.

What would move the needle is a test with high sensitivity for early high-grade serous disease, a low false-positive rate, and a randomized trial showing fewer deaths. None of the current contenders has cleared that bar.

Common myths about ovarian cancer screening and CA-125

Viral claims tend to contain a grain of truth polished into something misleading. Here are the ones circulating most widely, with the record corrected.

“A CA-125 test would have caught it early.” For about half of stage I cancers, CA-125 is normal. The test is most reliable when disease is already advanced. A single normal result in a woman with persistent symptoms is not reassurance; it is a reason to continue the workup with imaging.

“A new study proved ultrasound screening improves survival.” A single-arm program reported that women it screened and diagnosed survived longer than historical comparisons. Without a randomized control group, that result cannot separate real benefit from lead-time and length-time bias. The two randomized trials, one of which tested annual ultrasound in more than 50,000 women, found no reduction in deaths.

“My Pap smear checks my ovaries.” It checks the cervix for precancerous changes. It cannot see the ovaries or tubes and was never designed to.

“Doctors refuse the test to save money.” The test is inexpensive and widely available. Clinicians decline to order it for screening because randomized evidence shows it causes harm, chiefly surgery for false positives, without preventing deaths.

“If I feel fine, screening would find nothing anyway, so I am safe.” The opposite logic applies. Because no test is recommended, awareness of persistent new symptoms is the primary route to earlier diagnosis in average-risk women. Feeling fine is good news, but changes that last weeks deserve evaluation.

“Blood tests that detect many cancers can replace everything.” They are investigational for ovarian cancer, detect few early-stage tumors, and have not been shown to save lives. They do not replace any recommended screening, and they are not a reason to skip a conversation about symptoms or family history.

When to see a doctor

Because no routine ovarian cancer screening exists for most women, the clinician’s office rather than the screening suite is where earlier diagnosis actually happens. The principle is persistence and novelty, not any single symptom. Ovarian cancer symptoms are notoriously vague and overlap with digestive, urinary and gynecologic conditions that are far more common, which is why this is not a checklist to self-diagnose from. It is a guide to when a conversation is warranted.

Make an appointment if, for more than two to three weeks and on most days, you notice new bloating or a visibly swollen abdomen, pelvic or lower abdominal pain, feeling full quickly or losing appetite, or needing to urinate more often or more urgently than usual. The NHS and CDC both frame these as reasons to be checked, particularly in women over 50, precisely because persistence distinguishes them from an ordinary off week.

Seek care promptly, without waiting out the weeks, for red-flag signs: vaginal bleeding after menopause, unexplained weight loss, a lump you can feel in the abdomen, severe or worsening abdominal pain, persistent vomiting, or new shortness of breath with abdominal swelling. These warrant urgent evaluation whatever the cause turns out to be.

See a clinician on a separate track if your family history includes ovarian cancer in a parent, sibling or child; breast cancer before 50 or in multiple relatives; a known BRCA, Lynch or other hereditary cancer variant in the family; or Ashkenazi Jewish ancestry combined with any of the above. Ask specifically about referral for genetic counseling. The result determines whether you are a candidate for individualized monitoring or risk-reducing surgery.

Whatever you read online, including this article, the decision to order a CA-125, an ultrasound or any other test rests with the clinician who can examine you and weigh your history. If a result comes back abnormal, do not interpret it alone. Ask what it means in your situation, what the next step is, and whether a gynecologic oncologist should be involved.

Frequently asked questions

Is a CA-125 blood test a screening test for ovarian cancer?

No. CA-125 is used to monitor known ovarian cancer during and after treatment and to help assess a pelvic mass that has already been found. As a screening test in healthy women it misses about half of early-stage cancers and is raised by many benign conditions, which is why guidelines in the United States and United Kingdom recommend against using it that way.

What tests are done to check for ovarian cancer?

When symptoms or an examination raise concern, clinicians typically order a transvaginal ultrasound and a CA-125 blood test, sometimes with HE4 and the ROMA calculation. A CT or MRI scan maps any spread. The definitive diagnosis comes from surgery, where the mass is removed and examined by a pathologist, ideally by a gynecologic oncologist who can stage the disease in the same operation.

Can I ask my doctor for a CA-125 test just to be safe?

You can ask, and a good clinician will explain the trade-offs. For a woman with no symptoms and no inherited risk, an abnormal result is more likely to lead to anxiety, repeat tests and possibly unnecessary surgery than to find a treatable cancer. If you have persistent new symptoms or a concerning family history, the conversation changes, and the clinician decides what testing fits your situation.

How long can you have ovarian cancer without knowing?

There is no fixed answer. Slow-growing types can be present for years with few symptoms, while high-grade serous cancer, the most common lethal type, can spread within months of starting in the fallopian tube. Symptoms are often vague and attributed to digestion or aging, which is why persistence over weeks, rather than any single symptom, is the signal to seek evaluation.

What do people usually notice first with ovarian cancer?

Most women describe ordinary-sounding changes that would not have worried them individually: bloating that does not settle, a waistband that suddenly feels tight, feeling full after small meals, pelvic discomfort or needing the bathroom more often. The distinguishing feature is that they are new and persistent. This is not a list to self-diagnose from; it is a prompt to see a clinician if changes last beyond a few weeks.

Does a normal CA-125 mean I do not have ovarian cancer?

No. About half of women with stage I ovarian cancer have a normal CA-125, and some subtypes, such as mucinous and clear-cell tumors, often do not raise it at all. A normal result in a woman with persistent symptoms or a pelvic mass should not end the evaluation; imaging and specialist review are still needed. Your clinician will interpret the number alongside everything else.

Who qualifies as high risk and gets monitored for ovarian cancer?

Women with a confirmed pathogenic variant in BRCA1, BRCA2, or the Lynch syndrome genes, and those with variants in genes such as BRIP1, RAD51C, RAD51D or PALB2, are considered high risk. So are women with a strong family history before genetic results are known. They are offered genetic counseling, discussion of risk-reducing surgery, and in some cases interval CA-125 and ultrasound as a bridge.

Does a pelvic exam or Pap test screen for ovarian cancer?

Neither is an ovarian cancer screening test. The Pap and HPV tests sample the cervix and cannot detect disease in the ovaries or tubes. A pelvic examination can occasionally detect a large mass but misses early disease and was not shown to reduce deaths in trials. Both remain valuable for their intended purposes, and the exam is a reasonable first step when symptoms are present.

Did the ultrasound study showing better survival change the guidelines?

No. The study was a single-arm program without a randomized comparison group, so its survival figures are vulnerable to lead-time and length-time bias. The randomized UKCTOCS trial tested annual ultrasound in more than 50,000 women against no screening and found no reduction in deaths. Guidelines are built on randomized evidence, and none has changed as a result of the newer report.

Do multi-cancer blood tests screen for ovarian cancer?

Not yet in any recommended sense. These tests look for tumor DNA fragments in blood and can detect some advanced cancers, but sensitivity for early-stage ovarian cancer is low, and no randomized trial has shown they reduce deaths. They remain investigational for this purpose. Anyone considering one should discuss its limitations with a clinician rather than treating it as a replacement for evaluation of symptoms.

References

• CDC: Ovarian Cancer Screening
• MedlinePlus: CA-125 Blood Test (Ovarian Cancer)
• NHS: Ovarian cancer

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.